Merck Says R&D Efficiency Is Above Average, Rx Prices Not Tied To Research

The increasing cost of drug development will force companies to compete based on the efficiency of their R&D programs, Merck CEO Raymond Gilmartin suggested during a Nov. 30 Tufts Center for the Study of Drug Development briefing in Philadelphia